Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesity
- PMID: 39498282
- PMCID: PMC11532308
- DOI: 10.1016/j.obpill.2024.100133
Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesity
Abstract
Background: Lifestyle interventions (LIs) are the cornerstone for obesity management. The Mayo Clinic Diet (MCD) offers two approaches for LIs: the In-Person LI (IPLI) and the Digital Enhanced LI (DELI). The IPLI includes a 2-day in-person program with monthly follow-ups, whereas the DELI provides on-demand digital tools. The comparative efficacy of these approaches is currently unknown.
Methods: This retrospective study included two cohorts of adults with a body mass index (BMI) of ≥25 kg/m2 and weight metrics at least 3 months after starting either the IPLI or DELI program. The primary endpoint was the total body weight loss percentage (TBWL%) at 6 months.
Results: The study included 133 participants in the IPLI cohort (mean age 46.3 years, 65.4 % female, BMI 36.4) and 9603 in the DELI cohort (mean age 60.1 years, 85.0 % female, BMI 33.1). The DELI group achieved superior TBWL% at 1, 3, and 6 months compared to the IPLI group (3.4 % vs. 1.5 %, 4.7 % vs. 2.4 %, 5.3 % vs. 2.9 %, respectively; p < 0.001). After adjusting for age, gender, and starting weight, the DELI group maintained a higher TBWL% (difference 2.0 %; 95 % CI [1.0, 3.0], p < 0.001) and a greater proportion of participants achieved >5 % TBWL at 6 months (OR 1.66; 95 % CI [1.08, 2.55], p < 0.023).
Conclusion: The DELI approach resulted in superior weight loss outcomes compared to the IPLI. Further research is needed to explore how digital tools can improve weight loss effectiveness.
Keywords: Electronic health; Lifestyle interventions; Mobile health; Obesity.
© 2024 The Author(s).
Conflict of interest statement
Dr. Acosta is supported by NIH (NIH K23-DK114460). Dr Andres Acosta, and Mayo Clinic hold equity in Phenomix Sciences Inc. and are inventors of intellectual property licensed to Phenomix Sciences Inc. Dr Andres Acosta served as a consultant for Rhythm Pharmaceuticals, General Mills, Amgen, Bausch Health, RareStone; has contracts with Vivus Inc, Satiogen Pharmaceutical, and Rhythm Pharmaceutical.
Figures
References
-
- Ward Z.J., Bleich S.N., Cradock A.L., et al. Projected U.S. State-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–2450. - PubMed
-
- Waters HAOCSM, CA: milken institute. 2018. Print.
-
- Jensen M.D., Ryan D.H., Apovian C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol. 2014;63(25):2985–3023. Part B. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
